Premium
The Efficacy Results and Safety Profile of Imipenem/Cilastatin from the Clinical Research Trials
Author(s) -
Calandra G. B.,
Ricci F. M.,
Wang C.,
Brown K. R.
Publication year - 1988
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1988.tb05735.x
Subject(s) - imipenem/cilastatin , cilastatin , imipenem , antibiotics , pseudomonas aeruginosa , medicine , superinfection , adverse effect , clinical trial , microbiology and biotechnology , intensive care medicine , antibiotic resistance , bacteria , biology , immunology , virus , genetics
Imipenem/cilastatin is highly effective for infections in many body sites against a broad range of gram‐positive and gram‐negative aerobic and anaerobic bacteria. During therapy, development of resistance is uncommon except in the case of Pseudomonas aeruginosa in which the incidence appears similar to that for other beta‐lactam antibiotics. There appears to be a very low probability of cross‐resistance. The clinical and laboratory adverse reactions are similar in type to those for other beta‐lactam antibiotics. The frequency of colonization and superinfection during treatment with imipenem/cilastatin has been comparable to other antibiotics in comparative trials and to literature reports for other antibiotics for noncomparative trials.